Bristol-Myers Squibb Company has released the results of three post-hoc analyses from two Phase III pivotal trials that showed ORENCIA® (abatacept) improved daily activity participation, such as work or household chores, physical and social-role independence and sleep quality in adult rheumatoid arthritis (RA) patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists.
These data are from post-hoc analyses of two Phase III pivotal trials investigating ORENCIA: AIM (Abatacept in Inadequate responders to Methotrexate) and ATTAIN (Abatacept Trial in Treatment of Anti-TNF Inadequate Responders).
"The chronic nature of RA can have a significant impact on a person’s health-related quality of life, including independence, ability to perform daily activities and sleep quality," said George Wells, MSc, PhD, professor of the Department of Epidemiology and Community Medicine, University of Ottawa.
ORENCIA is indicated in the United States for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs, such as methotrexate or TNF antagonists.
